Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10067-008-1000-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Autoimmune Enteritis in an Adult With Psoriatic Arthritis, Successfully Treated With Glucocorticoids and Adalimumab.
Cureus
December 2024
Rheumatology, Rochester Regional Health, Rochester, USA.
Article Synopsis
- Autoimmune enteritis (AIE) is a rare and severe condition that mainly leads to persistent diarrhea and malnutrition, often diagnosed in infants but can occur in adults.
- A male patient in his 60s with a history of psoriasis developed intractable diarrhea despite various treatments and ultimately required total parenteral nutrition.
- After biopsies confirmed AIE, he was treated with prednisone, budesonide, and adalimumab, leading to significant improvement and normalization of his bowel habits.
A Comprehensive Review on Plant Bioactive Compounds-Based Novel Drug Delivery System for the Treatment of Rheumatoid Arthritis.
Pharm Nanotechnol
December 2024
Rungta College of Pharmaceutical Sciences and Research, Pharmacy, Kohka, Bhilai (C.G.), India.
Rheumatoid Arthritis (RA) is a chronic autoimmune disorder characterized by inflammation in the joints, leading to pain, swelling, stiffness, and eventual joint damage. This condition occurs when the body's immune system mistakenly attacks the synovium, the lining of the membranes surrounding the joints. Treatment focuses on reducing inflammation, alleviating pain, and preventing joint damage through a combination of medications, physical therapy, and lifestyle modifications.
View Article and Find Full Text PDFEffectiveness of Anti-tumor Necrosis Factor Drugs on Hidradenitis Suppurativa: A Systematic Review.
Cureus
November 2024
Pharmacology, St. George's University School of Medicine, St. George's, GRD.
Hidradenitis suppurativa (HS) is a painful and chronic inflammatory skin disease with no consistently effective treatment, affecting a significant portion of the Western population. HS is characterized by painful nodules, abscesses, tunnels, and scarring in body folds. The immunobiology is poorly understood, therefore resulting in a lack of effective therapies.
View Article and Find Full Text PDFSystematic review of biologic use for psoriasis in HIV-positive individuals from 2018 to 2024.
Arch Dermatol Res
November 2024
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
Article Synopsis
- - Psoriasis is a long-term inflammatory skin condition linked to T-lymphocyte activation, and treating it in individuals with HIV is challenging due to immune system complications.
- - This study reviewed 19 articles involving 24 cases of psoriasis in people with HIV, analyzing various therapies like apremilast and ustekinumab, which showed effectiveness in reducing skin symptoms and even some cases of psoriatic arthritis.
- - Although adverse events were rare and manageable, more comprehensive research is needed to clearly understand the safety and efficacy of these treatments for HIV-positive patients.
Trends in New Use of Disease-Modifying Antirheumatic Drugs for Juvenile Idiopathic Arthritis Among Commercially Insured Children in the United States from 2001 to 2022.
Arthritis Rheumatol
October 2024
Rutgers University, New Brunswick, New Jersey.
Objective: The objective of this study is to describe recent trends in disease-modifying antirheumatic drug (DMARD) use for children with juvenile idiopathic arthritis (JIA) in the United States.
Methods: We used commercial claims data (2000-2022) to perform a serial cross-sectional utilization study of children aged 1 to 18 that were diagnosed with JIA. Initiations of conventional synthetic DMARDs (csDMARDs), biologic DMARDs (bDMARDs), or targeted synthetic DMARDs (tsDMARDs) were identified after a ≥12-month baseline and expressed as a percentage of all new DMARD initiations per year, by category, class, and individual agent.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!